Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II therapeutic vaccine trial (CVP-NASVAC) in chronic hepatitis B carriers (HepBVac-P2ASC)
jRCTs061210087Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Chronic Hepatitis B (CHB) comparing CVP-NASVAC with Placebo (2 arms). Primary endpoints: HBsAg reduction and HBsAg loss rate. Started Jun 2022; status: recruiting.
02
Drugs
ABX203
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCTs061210087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210087.